Next Article in Journal
The Mechanism of Action of Cyclophosphamide and Its Consequences for the Development of a New Generation of Oxazaphosphorine Cytostatics
Previous Article in Journal
Sphenopalatine Ganglion Stimulation Upregulates Transport of Temozolomide across the Blood-Brain Barrier
Open AccessArticle

Prevalence of Adverse Drug Events in Severely Obese Adults and Associated Factors: Clinical Trial Baseline Results

1
Post-Graduate Program in Health Sciences, School of Medicine, Federal University of Goiás, Goiás 74605-050, Brazil
2
School of Medicine, Federal University of Goiás, Goiás 74605-050, Brazil
3
United Faculty of Campinas, Goiás 74535-280, Brazil
4
Goiás Health Department, Goiás 74860-270, Brazil
5
School of Pharmacy, Federal University of Goiás, Goiás 74605-170, Brazil
*
Authors to whom correspondence should be addressed.
Sci. Pharm. 2020, 88(4), 41; https://doi.org/10.3390/scipharm88040041
Received: 12 August 2020 / Revised: 4 September 2020 / Accepted: 15 September 2020 / Published: 23 September 2020
Drugs are the most widely used therapeutic tool for treatment of diseases. However, misuse can lead to an adverse drug event (ADE) in susceptible individuals such as those that are severely obese. This study aimed to describe the frequency of ADEs, the associations of ADEs with anatomical therapeutic chemical classes and their respective frequency, estimate the prevalence of ADEs, and analyse factors associated with ADE in adults with severe obesity. Cross-sectional analysis of baseline data from a randomized clinical trial in the central-western region of Brazil. A total of 150 individuals aged 18–65 years with a Body Mass Index of 35 kg/m2 were included. The outcome variable was the presence of ADE and the explanatory variables were socio-demographic factors, lifestyle, health, and medication use. ADEs were associated with use of drugs for the digestive tract and metabolism (p < 0.001) and the cardiovascular system (p < 0.001). The prevalence of ADEs was 32.67% (n = 49) and associated with the age range 40 to 49 years (p = 0.033), diabetes (p = 0.004), multimorbidities ≥ 4 (p = 0.009), self-medication (0.031), and presence of potential drug interactions (0.017). The prevalence of ADEs was high and was associated with drugs commonly used in treatment of obesity-related morbidities and self-medication. The introduction of a pharmacist to multi-professional teams can improve medication safety for severely obese patients. View Full-Text
Keywords: severe obesity; adverse drug events; drug utilization reviews; randomized controlled trial; pharmacoepidemiology; diabetes mellitus; multimorbidities; self-medication severe obesity; adverse drug events; drug utilization reviews; randomized controlled trial; pharmacoepidemiology; diabetes mellitus; multimorbidities; self-medication
MDPI and ACS Style

Modesto, A.C.F.; Silveira, E.A.; Santos, A.S.A.C.; Rodrigues, A.P.S.; Lima, D.M.; Provin, M.P.; Amaral, R.G. Prevalence of Adverse Drug Events in Severely Obese Adults and Associated Factors: Clinical Trial Baseline Results. Sci. Pharm. 2020, 88, 41.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop